|1.||Chalmers, John: 27 articles (10/2015 - 01/2003)|
|2.||Woodward, Mark: 23 articles (10/2015 - 04/2009)|
|3.||Patel, Anushka: 20 articles (12/2014 - 08/2006)|
|4.||Poulter, Neil: 19 articles (01/2015 - 04/2009)|
|5.||Zoungas, Sophia: 18 articles (10/2015 - 08/2009)|
|6.||ADVANCE Collaborative Group: 15 articles (10/2015 - 01/2007)|
|7.||Williams, Bryan: 14 articles (10/2015 - 04/2009)|
|8.||Hamet, Pavel: 14 articles (01/2015 - 04/2009)|
|9.||Neal, Bruce: 13 articles (10/2015 - 04/2009)|
|10.||Mancia, Giuseppe: 13 articles (10/2014 - 04/2009)|
|1.||Type 2 Diabetes Mellitus (MODY)
11/01/1993 - "The results of this study appear to confirm the established efficacy of gliclazide in treating NIDDM."
01/01/1991 - "Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM."
01/01/1985 - "In an assessment of carbohydrate and amino acid metabolism in 9 patients with non-insulin-dependent diabetes mellitus (NIDDM) before and after 3 months' therapy with gliclazide, glycaemic control was improved (mean +/- S.D. "
09/28/2005 - "[A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus]."
12/01/1997 - "Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study."
|2.||Vascular Diseases (Vascular Disease)
06/24/1991 - "Pathophysiology of vascular disease in diabetes: effects of gliclazide."
10/01/1994 - "From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease."
10/01/2015 - "A case-cohort study was performed in 3,763 participants with prevalent diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. "
08/01/2014 - "The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial showed an increase in all-cause mortality with intensive glycemic control, whereas the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study and Veteran's Affairs Diabetes Trial (VADT) showed no benefit with aggressive glycemic control. "
08/01/2014 - "We performed a case-cohort study, including 439 incident cases of microvascular events (new or worsening nephropathy or retinopathy) and 2,946 noncase subjects identified from participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. "
03/01/1999 - "These results suggest that gliclazide may be beneficial in the prevention of endothelial disturbances associated with hyperglycemia in diabetic patients."
03/01/2006 - "In this small study of gliclazide dose escalation in patients with type 2 DM and postprandial hyperglycemia, gliclazide 80 mg/d was associated with a reduction in postprandial hyperglycemia. "
03/01/2007 - "In the type 2 diabetic patients treated with gliclazide, short-term, intensive, submaximal exercise, performed 2 h after a meal, causes reduction of hyperglycemia during the recovery period. "
05/01/2006 - "Gliclazide is an oral hypoglycemic agent that belongs to the class of sulfonylureas: basic and clinical evidences suggest that gliclazide works as an antioxidative drug, independently from its ability to reduce hyperglycemia. "
03/01/1990 - "Gliclazide taken 30 minutes before breakfast increased in serum concentration before the meal-induced hyperglycemia, but that taken just before or just after breakfast was poorly absorbed and showed smaller and greatly delayed peaks. "
06/01/2010 - "In conclusion, the present study showed that gliclazide did not affect NER and NHEJ in human normal cells, but it may stimulate DNA repair in cancer cells."
06/01/2010 - "The results of clinical studies revealed that gliclazide may reduce the risk of cancer in type 2 diabetic patients (T2DM), although the mechanism of possible protective effect is not sufficiently explored. "
05/01/2012 - "Our findings indicate that gliclazide may protect both normal and cancer human cells against apoptosis induced by H(2)O(2). "
05/01/2012 - "Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells."
09/25/2006 - "These results suggest that gliclazide may diminish the risk of free radical-related diseases associated with type 2 diabetes mellitus and possibly cancer."
03/28/2003 - "A hypoglycemic sulfonylurea, gliclazide, is known to be a general free radical scavenger and its beneficial effects on diabetic complications have been documented. "
02/01/2000 - "These findings suggest that gliclazide is not only effective in reducing blood sugar, but may also be beneficial as a result of inhibition of lipid and protein denaturation, which is believed to lead to the development of diabetic complications."
05/01/1997 - "These findings suggest that gliclazide is not only effective in reducing blood sugar but also may be beneficial by inhibition of lipid and protein denaturation, which leads to the development of diabetic complications."
09/01/1995 - "3. Insulin and gliclazide treatment increases SOD activity and delays late diabetic complications."
06/17/2008 - "These results suggest that gliclazide may protect against the oxidative stress-related chronic diabetes complications, including cancer, by decreasing the level of DNA damage induced by reactive oxygen species."
|3.||Blood Glucose (Blood Sugar)
|4.||perindopril drug combination indapamide
|1.||Diet Therapy (Therapy, Diet)